American Society of Hirudotherapy

Cutis Marmorata Telangiectatica Congenita (Investigational)

Highly investigational; supportive care and monitoring of associated anomalies remain primary; case reports only for adjunctive use.

Tier C — InvestigationalInvestigationalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for cutis marmorata telangiectatica congenita. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
What evidence exists?
Tier C (investigational). No controlled-trial evidence. CMTC is a congenital vascular malformation that typically improves spontaneously over the first 2-5 years of life. Evidence-based management is observation with regular pediatric and dermatologic monitoring, screening for associated anomalies (limb asymmetry, glaucoma, neurologic findings), and pulsed-dye laser for persistent telangiectatic components in older children. Most cases need no active treatment.
Main risks
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Risks magnified in children — leech therapy is generally inappropriate in pediatric patients
  • Bleeding into vascular malformation tissue
  • Worsening of telangiectatic pattern from inflammatory bite injury
Who should not consider this
  • Children under 18 (insufficient pediatric safety data; CMTC also improves spontaneously)
  • Patients without screening for associated anomalies (limb asymmetry, glaucoma, neurologic features)
  • Anyone considering CMTC treatment as cosmetic — the malformation is benign and usually improves
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL)
  • People with an active infection at the planned application site
What to ask your clinician
  • Has my CMTC been confirmed by dermatology and have associated anomalies been screened for?
  • Is treatment medically necessary, or is observation appropriate?
  • Has pulsed-dye laser been considered for the telangiectatic component?
  • What is the published safety record for leech therapy in vascular malformations?
  • What is the risk that bleeding into the malformation worsens the appearance?
  • Will success be measured against the natural improvement that CMTC already shows over time?
When to seek urgent care
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • New limb-length discrepancy, vision changes, seizure, or neurologic symptom (could indicate progression of associated anomalies)
  • Ulceration or progressive enlargement of the malformation

What this does NOT mean

  • It does not mean leech therapy is FDA-cleared for CMTC — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace observation, which is the standard of care for most cases.
  • It does not modify the underlying vascular malformation.
  • It is not appropriate for pediatric patients, who make up most CMTC cases.
  • It does not have any controlled evidence and may worsen the visible vascular pattern.

Safety cross-references

Clinical Profile

Category
dermatological
ICD-10
Q82.8, R23.8
Safety tier
high

Evidence Summary

Cutis marmorata telangiectatica congenita (CMTC) is a sporadic congenital cutaneous vascular anomaly characterized by reticulated erythema and telangiectasia, often improving spontaneously in early childhood. Approximately 20 percent of cases have associated anomalies (limb asymmetry, glaucoma, neurologic findings) requiring multidisciplinary workup. No specific treatment is established for the cutaneous manifestation; pulsed dye laser may be considered for residual telangiectasias. No controlled clinical trial, and no published case report, of leech therapy for cutis marmorata telangiectatica congenita exists; any use would be investigational and mechanistic only. Pediatric CMTC is not an appropriate indication.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Wollina U (2008)0

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Pediatric patients
  • Concurrent unevaluated associated anomalies (limb, ocular, neurologic)
  • Facial placement
  • Telangiectatic plaque overlying a major vessel

Related Conditions

Livedo Reticularis

Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.

Lipodermatosclerosis

Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.

Insulin Injection Lipohypertrophy

Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.

Androgenic Alopecia

Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.

Explore the evidence base

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Cutis Marmorata Telangiectatica Congenita (Investigational) — Hirudotherapy Evidence | ASH